Clinical Scorecard: Vaginal Laser Therapy and Sexual Health in Breast Cancer Survivors Taking Aromatase Inhibitors: A Secondary Analysis
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Vaginal Laser Therapy and Sexual Health in Breast Cancer Survivors Taking Aromatase Inhibitors
Key Mechanisms
Aromatase inhibitors suppress estrogen and severely worsen GSM symptoms; the trial compared fractional carbon dioxide laser therapy with sham laser therapy.
Target Population
Population described in the source article.
Care Setting
Care setting described in the source article.
Key Highlights
This exploratory secondary analysis assessed sexual outcomes through 12 months in participants from the LIGHT randomized clinical trial.
Eighty-four participants were randomized equally to fractional carbon dioxide laser therapy or sham laser therapy, with five monthly sessions scheduled in each group.
The primary endpoint was the between-group difference in change in Female Sexual Function Index total score from baseline to month 12.
Secondary outcomes included dyspareunia, sexual activity, body image, quality of life, vaginal health, objective vaginal measures, and safety.
All participants received first-line nonhormonal moisturizers and/or lubricants and vibrators, regardless of randomized group.
Guideline-Based Recommendations
Diagnosis
Management
The article reports that most regulatory bodies and medical societies recommend against vaginal energy-based therapy outside investigational protocols.
All participants received first-line over-the-counter nonhormonal moisturizers and/or lubricants and vibrators at no cost.
Monitoring & Follow-up
Sexual function was assessed with the validated Spanish Female Sexual Function Index at baseline and at 6- and 12-month follow-up.
Risks
Patient & Prescribing Data
The analysis included 84 breast cancer survivors receiving aromatase inhibitors who had GSM and dyspareunia; participants could be sexually active or not sexually active but interested in future sexual activity.
Participants were randomized to five monthly sessions of fractional carbon dioxide laser therapy or sham laser therapy. All received first-line nonhormonal moisturizers and/or lubricants and vibrators at no cost.
Clinical Best Practices
The authors state that investigational protocols should include women who are not sexually active but expect to resume sexual activity once vaginal symptoms improve.
The authors report that most regulatory bodies and medical societies recommend against vaginal energy-based therapy beyond investigational protocols and call for sham-controlled randomized clinical trials.
